Synthesis and SAR of 4-(3-hydroxyphenylamino)pyrrolo[2,1-f][1,2,4]triazine based VEGFR-2 kinase inhibitors

Bioorganic and Medicinal Chemistry Letters

Volumn 15, Issue 5, 2005, Pages 1429-1433

  Borzilleri, Robert M ^a   Cai, Zhen Wei ^a   Ellis, Christopher ^a   Fargnoli, Joseph ^a   Fura, Aberra ^a   Gerhardt, Tracy ^a   Goyal, Bindu ^a   Hunt, John T ^a   Mortillo, Steven ^a   Qian, Ligang ^a   Tokarski, John ^a   Vyas, Viral ^a   Wautlet, Barri ^a   Zheng, Xioping ^a   Bhide, Rajeev S ^a  

^a BRISTOL MYERS SQUIBB   (United States)

Author keywords

Angiogenesis; Kinase receptor; SAR; VEGFR 2

Indexed keywords

4 (3 HYDROXY 4 METHYLPHENYLAMINO)PYRROLO[2,1 F][1,2,4]TRIAZINE; PHENOL DERIVATIVE; PHOSPHOTRANSFERASE INHIBITOR; TRIAZINE DERIVATIVE; UNCLASSIFIED DRUG; VASCULOTROPIN INHIBITOR; VASCULOTROPIN RECEPTOR 2;

ARTICLE; DRUG POTENCY; DRUG SYNTHESIS; GLUCURONIDATION; HUMAN; HUMAN CELL; MOUSE; NONHUMAN; STRUCTURE ACTIVITY RELATION;

EID: 13944258781     PISSN: 0960894X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bmcl.2004.12.079     Document Type: Article

References (16)

1. J. Folkman Nat. Med. 1 1995 27 31
2. P. Carmeliet, and R.K. Jain Nature 407 2000 249 257
3. D.R. Robinson, Y.M. Wu, and S.F. Lin Oncogene 19 2000 5548 5557
4. L.B. Jakeman, J. Winer, G.L. Bennett, C.A. Altar, and N. Ferrara J. Clin. Invest. 89 1992 244 253
5. D.W. Kim, B. Lu, and D.E. Hallahan Curr. Opin. Invest. Drugs 5 2004 597 604
6. J.C. Yang, L. Haworth, R.M. Sherry, P. Hwu, D.J. Schwartzentruber, S.L. Topalian, S.M. Steinberg, H.X. Chen, and S.A. Rosenberg New Engl. J. Med. 349 2003 427 434
7. H. Hurwitz, L. Fehrenbacher, W. Novotny, T. Cartwright, J. Hainsworth, W. Heim, J. Berlin, A. Baron, S. Griffing, E. Holmgren, N. Ferrara, G. Fyfe, B. Rogers, R. Ross, and F. Kabbinavar New Engl. J. Med. 350 2004 2335 2342
8. J.T. Hunt, T. Mitt, R. Borzilleri, J. Gullo-Brown, J. Fargnoli, B. Fink, W.-C. Han, S. Mortillo, G. Vite, B. Wautlet, T. Wong, C. Yu, X.-P. Zheng, and R. Bhide J. Med. Chem. 47 2004 4054 4059
9. 2.5 μM ATP concentration was used in the enzyme assay
10. For the detailed experimental see: Hunt, J. T.; Bhide, R. S.; Borzilleri, R. M.; Qian, L. PCT Int. Appl. WO 2000071129
11. An alternate synthesis of pyrroles 2 could be accomplished using the published route: M. Suzuki, M. Miyoshi, and K. Matsumoto J. Org. Chem. 39 1974 1980
12. W. Klötzer, H. Baldinger, E.-M. Karpitschka, and J. Knoflach Synthesis 1982 592
13. The rate of glucuronidation was determined under the following conditions: substrate concentration, 20 μM; protein concentration, 2 mg/mL; UDPGA, 5 mM; pH 7.5 Tris buffer, 100 mM; magnesium chloride, 10 mM; alamethicine (in ethanol), 2.5 μg/mL. Incubations were performed at 37°C and were initiated by the addition of UDPGA. 200 μL aliquots were taken at times 0, 10, and 20 min and the reaction terminated by the addition of equal volume of acetonitrile. Following vortexing and centrifugation, 20 μL aliquot was analyzed by HPLC-UV. The percentage of compound remaining at each time point was calculated and compared to the values at zero time point. The rate of metabolism was calculated by determining the nanomoles of compound that disappeared and dividing it by the time of incubation and the milligram of protein
14. 3OD, 300 MHz) of compound 27: δ 7.80 (s, 1H), 7.55 (s, 1H), 7.01 (d, 1H, J = 8 Hz), 6.77 (s, 1H), 6.64 (d, 1H, J = 8 Hz), 3.60-3.47 (m, 3H), 3.29-3.26 (m, 2H), 3.12-3.10 (m, 2H), 3.08-2.89 (m, 2H), 2.04 (s, 3H), 1.99-1.95 (m, 2H), 1.891.82 (m, 3H), 1.32 (d, 6H, J = 7 Hz)
15. M.A. McTigue, J.A. Wickersham, C. Pinko, R.E. Showalter, C.V. Parast, A. Tempczyk-Russell, M.R. Gehring, B. Mroczkowski, C.-C. Kan, J.E. Villafranca, and K. Appelt Structure 7 1999 319
16. L. Shewchuk, A. Hassell, B. Wisely, W. Rocque, W. Holmes, J. Veal, and L. Kuyper J. Med. Chem. 43 2000 133